Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus
Grades severity of hyperglycemia secondary to immune checkpoint inhibitor therapy.
INSTRUCTIONS
Use in adult patients with signs and symptoms of new or worsening hyperglycemia that developed while on treatment with immune checkpoint inhibitors.
When to Use
Pearls/Pitfalls
Why Use
Asymptomatic or mild symptoms; fasting glucose value >160 mg/dL (>8.9 mmol/L); no evidence of ketosis or laboratory evidence of T1DM
Moderate symptoms, able to perform ADLs, fasting glucose value >160-250 mg/dL (>8.9-13.9 mmol/L), ketosis or evidence of T1DM at any glucose level
Severe symptoms, medically significant or life-threatening consequences, unable to perform ADLs; fasting glucose level >250-500 mg/dL (>13.9-27.8 mmol/L)
Severe symptoms, medically significant or life-threatening consequences, unable to perform ADLs; fasting glucose level >500 mg/dL (>27.8 mmol/L)
Result:
Please fill out required fields.